Get started

Financials · BDSX

Biodesix Inc. (BDSX) financials

For the twelve months ended Sep 30, 2026, Biodesix Inc. reported $105.21M of revenue and -$27.08M of net income.

Revenue, TTM
$105.21M
Revenue growth, YoY
+31.2%
Net income, TTM
-$27.08M
Net margin
-25.7%
Free cash flow, TTM
-$19.07M
EPS, diluted, TTM
-$2.70
Cash
$28.41M
Total debt
$50.00M
P/S
1.09
Market cap
$114.7M
Annual revenue$88.50M
FY2019FY2025
Annual net income-$35.27M
FY2019FY2025
Annual free cash flow-$23.53M
FY2019FY2025

BDSX revenue and earnings growth

BDSX revenueQ3 2026$24.04M

Quarter YoY
+10.4%
QoQ
-10.5%
FY YoY
+24.1%
5Y CAGR
+14.2%

BDSX revenue was $24.04M in fiscal Q3 2026 (ended Sep 30, 2026), up 10.4% from a year earlier and down 10.5% from the prior quarter. For the full fiscal 2025 it was $88.50M, up 24.1% from fiscal 2024. Compound annual growth was +14.2% over 5 years. It rose in 5 of the last 6 fiscal years. Fiscal 2025 is the highest of the 7 fiscal years on file.

BDSX net incomeQ3 2026-$8.03M

BDSX net income was -$8.03M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$8.72M a year earlier. For the full fiscal 2025 it was -$35.27M, compared with -$42.93M in fiscal 2024.

BDSX EPSQ3 2026-$0.75

BDSX diluted EPS was -$0.75 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$4.67, compared with -$6.64 in fiscal 2024.

BDSX free cash flowQ3 2026-$7.76M

BDSX free cash flow was -$7.76M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$8.93M a year earlier. For the full fiscal 2025 it was -$23.53M, compared with -$51.88M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$88.50M$71.32M$49.09M$38.21M$54.51M$45.56M$24.55M
Research and development$12.00M$9.56M$9.99M$13.10M$12.79M$10.82M$10.47M
Selling, general and admin$87.55M$80.45M$67.39M$61.46M$50.52M$34.86M$30.64M
Operating income-$27.87M-$34.50M-$41.34M-$50.59M-$40.94M-$22.93M-$26.74M
Interest expense$7.72M$8.26M$9.54M$8.07M$4.51M$7.60M$3.01M
Income tax$0$0$0$0$0$0-
Net income-$35.27M-$42.93M-$52.15M-$65.45M-$43.16M-$65.45M-$30.73M
EPS, basic-$4.67-$6.64-$12.80-$31.00-$31.60-$129.60-$2539.40
EPS, diluted-$4.67-$6.64-$12.80-$31.00-$31.60-$129.60-$2539.40
Diluted shares7.6M6.5M4.1M2.1M1.4M241,90012,100

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$18.99M$26.33M$26.37M$43.17M$32.80M$62.31M$5.47M
Receivables$9.04M$8.60M$7.68M$5.07M$3.66M$15.30M$5.29M
Current assets$32.52M$39.48M$39.68M$53.33M$43.61M$86.14M$12.70M
Goodwill$15.03M$15.03M$15.03M$15.03M$15.03M$15.03M$15.03M
Total assets$87.48M$97.24M$99.10M$92.91M$76.10M$121.07M$45.03M
Current liabilities$17.44M$14.32M$33.42M$22.84M$28.96M$32.13M$22.60M
Total debt$47.45M$36.43M$35.28M$25.05M$10.01M$27.77M$35.97M
Total liabilities$89.94M$76.37M$94.52M$72.30M$56.37M$79.90M$76.21M
Shareholders' equity-$2.46M$20.88M$4.58M$20.61M$19.73M$41.17M-$225.14M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow-$23.27M-$48.65M-$22.87M-$44.97M-$28.22M-$21.37M-$21.73M
Capital expenditures$259.0K$3.23M$22.92M$3.30M$2.24M$1.95M$1.31M
Free cash flow-$23.53M-$51.88M-$45.79M-$48.27M-$30.46M-$23.31M-$23.04M
Investing cash flow-$403.0K-$3.44M-$23.06M-$3.53M-$2.55M-$2.93M-$1.87M
Financing cash flow$16.42M$52.05M$29.13M$58.88M$1.26M$81.13M$22.97M
Stock-based compensation$4.14M$6.64M$5.37M$5.96M$4.94M$3.71M$170.0K
Depreciation and amortization$5.67M$5.77M$3.33M$3.60M$3.18M$2.90M$2.79M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY24.1%45.3%28.5%-29.9%19.6%85.6%-
Operating margin-31.5%-48.4%-84.2%-132.4%-75.1%-50.3%-108.9%
Net margin-39.8%-60.2%-106.2%-171.3%-79.2%-143.7%-125.1%
Free cash flow margin-26.6%-72.7%-93.3%-126.3%-55.9%-51.2%-93.8%
Return on equity--205.6%-1138.6%-317.6%-218.8%-159.0%-
Return on assets-40.3%-44.1%-52.6%-70.4%-56.7%-54.1%-68.2%
Current ratio1.862.761.192.341.512.680.56
Debt to equity-1.757.701.220.510.67-

Source: XBRL data Biodesix Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Nov 3, 2025.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BDSX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
BDSX$105.21M+31.2%-$27.08M-25.7%$114.7M
UNH$449.66B+3.3%$15.88B3.5%$356.28B
ELV$201.83B+3.6%$5.13B2.5%$90.37B
CI$286.32B+6.8%$5.99B2.1%$77.89B
HUM$154.19B+22.0%$1.25B0.8%$50.82B
NTRA$2.91B+37.4%-$164.71M-5.7%$46.46B
CNC$203.90B+9.7%$1.46B0.7%$33.93B
ILMN$4.54B+5.8%$895.00M19.7%$33.38B
LH$14.59B+6.0%$1.00B6.9%$30.19B

BDSX FAQ

8 questions
  • What is BDSX revenue?
    Biodesix Inc. (BDSX) reported $105.21M of revenue for the twelve months ended Sep 30, 2026. That is up 31.2% from the year before. Revenue for fiscal 2025 was $88.50M.
  • Is BDSX profitable?
    No. Biodesix Inc. reported a net loss of $27.08M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does BDSX have?
    Biodesix Inc. reported $28.41M in cash and cash equivalents and $50.00M of debt on its most recent balance sheet in SEC filings.
  • How fast is BDSX revenue growing?
    Biodesix Inc.'s revenue changed +24.1% in fiscal 2025, to $88.50M. Its compound annual growth rate was +14.2% over 5 years.
  • What is BDSX free cash flow?
    Biodesix Inc. generated -$19.07M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$18.16M less capital expenditures.
  • What is BDSX earnings per share?
    Diluted earnings per share were -$2.70 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did BDSX last report financial results?
    The latest statements here come from Biodesix Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this BDSX financial data come from?
    Quantisnow builds these statements from the structured XBRL data Biodesix Inc. files with the SEC. It is provided for information only and is not investment advice.